Table 2.
Nanoparticle-based cancer immunotherapy in clinical trials
| Generic name | Nanoparticle platform | Cancer type | Status | Ref |
|---|---|---|---|---|
| JVRS-100 | Lipid NP | Leukemia | Phase 1 | 144 |
| DPX-Survivac | Liposome | Refractory diffuse large B-cell lymphoma | Phase 2 | 145 |
| Lipovaxin-MM | Liposome | Metastatic melanoma | Phase 1 | 146 |
| DPX-0907 | Liposome | Advanced stage breast, ovarian and prostate cancer | Phase 1 | 147 |
| WDVAX | PLGA | Metastatic melanoma | Phase 1 | 148 |
| CYT-6091 | Colloidal gold | Advanced solid tumors | Phase 1 | 149, 150 |
| IMF-001 | NP complex | Esophageal cancer | Phase 1 | 151, 152 |